In particular, here we have directed our first effort to inhibit Notch2 activation trigged by the ligand Jagged2 on the basis of our interest in multiple myeloma, an hematological malignancy associated to Notch2/Jagged2 dysregulation. The gene discussed is NOTCH2; the disease is plasma cell myeloma.